CTMX has been the topic of several other reports. Wedbush reduced their target price on CytomX Therapeutics from $35.00 to $25.00 and set an outperform rating on the stock in a research report on Wednesday, February 27th. Zacks Investment Research downgraded CytomX Therapeutics from a hold rating to a sell rating in a research report on Tuesday, April 30th. SunTrust Banks reduced their target price on CytomX Therapeutics to $18.00 and set a buy rating on the stock in a research report on Thursday, February 28th. ValuEngine downgraded CytomX Therapeutics from a hold rating to a sell rating in a research report on Wednesday, May 1st. Finally, Barclays initiated coverage on CytomX Therapeutics in a report on Monday, March 11th. They issued an overweight rating and a $16.00 price objective on the stock. Two research analysts have rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the stock. The company presently has a consensus rating of Buy and an average price target of $21.03.
Shares of CTMX traded down $0.41 during trading hours on Tuesday, reaching $9.97. 247,890 shares of the company traded hands, compared to its average volume of 486,790. The company has a quick ratio of 4.21, a current ratio of 4.21 and a debt-to-equity ratio of 0.22. The firm has a market cap of $512.47 million, a P/E ratio of -4.91 and a beta of 0.57. CytomX Therapeutics has a fifty-two week low of $8.94 and a fifty-two week high of $27.20.
In other CytomX Therapeutics news, General Counsel Lloyd A. Rowland acquired 9,000 shares of the stock in a transaction on Monday, March 4th. The stock was purchased at an average price of $10.33 per share, for a total transaction of $92,970.00. Following the purchase, the general counsel now directly owns 9,979 shares in the company, valued at $103,083.07. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 6.30% of the stock is owned by company insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Legal & General Group Plc grew its position in shares of CytomX Therapeutics by 15.3% in the 3rd quarter. Legal & General Group Plc now owns 7,036 shares of the biotechnology company’s stock worth $130,000 after acquiring an additional 934 shares in the last quarter. Virtus ETF Advisers LLC grew its position in shares of CytomX Therapeutics by 8.3% in the 4th quarter. Virtus ETF Advisers LLC now owns 20,415 shares of the biotechnology company’s stock worth $308,000 after acquiring an additional 1,565 shares in the last quarter. Wedbush Securities Inc. grew its position in shares of CytomX Therapeutics by 8.1% in the 4th quarter. Wedbush Securities Inc. now owns 25,355 shares of the biotechnology company’s stock worth $383,000 after acquiring an additional 1,900 shares in the last quarter. Northern Trust Corp grew its position in shares of CytomX Therapeutics by 0.4% in the 1st quarter. Northern Trust Corp now owns 542,020 shares of the biotechnology company’s stock worth $5,827,000 after acquiring an additional 2,031 shares in the last quarter. Finally, Swiss National Bank grew its position in shares of CytomX Therapeutics by 3.2% in the 1st quarter. Swiss National Bank now owns 77,900 shares of the biotechnology company’s stock worth $837,000 after acquiring an additional 2,400 shares in the last quarter. Hedge funds and other institutional investors own 81.83% of the company’s stock.
CytomX Therapeutics Company Profile
CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 immuno-oncology target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel drug target; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target.
Featured Article: What is the downside to momentum investing?
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.